Jim Shrine

Array BioPharma Inc. raised $91 million in a public offering of stock, money that will be used to fund development of its broad, early stage pipeline of small-molecule drug candidates for cancer and inflammatory diseases. (BioWorld Today)

Array Raises $91M Publicly For Cancer, Inflammation Programs

May 3, 2007

By Jim Shrine

Array BioPharma Inc. raised $91 million in a public offering of stock, money that will be used to fund development of its broad, early stage pipeline of small-molecule drug candidates for cancer and inflammatory diseases. (BioWorld Today)

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

May 2, 2007

By Jim Shrine

Jim Shrine

ARTICLES

Marcadia Raises $15M In First Round For Metabolic Programs

ProCertus Completes Series A Financing For Cancer Programs

ProCertus Completes Series A Financing For Cancer Programs

Avid Raises $26M In Series C For Molecular imaging Agents

Avid Raises $26M In Series C For Molecular imaging Agents

Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88

Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88

Array Raises $91M Publicly For Cancer, Inflammation Programs

Array Raises $91M Publicly For Cancer, Inflammation Programs

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

Today's news in brief

Today's news in brief

News in brief

Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

KT-621: a first-in-class STAT6 degrader for Th2-driven diseases